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Correction to: British Journal of Cancer (2007) 96, 1293—1301.
doi:10.1038/6603696
In the abstract of the above paper, a peptide with correct
sequence (TLMKKDKYTL) is mentioned. This sequence
should also appear in Table 1 as the sequence of peptide
60031. Unfortunately, an incorrect sequence (ALSPASSRSV)
was included in Table 1 (all other data in the respective line
of the table are correct and refer to peptide TLMKKDKYTL).
The corrected Table 1 is shown below.
Table 1 Prediction of HLA-A*0201-restricted SOX2-derived peptides and determination of binding affinities by a competition assay
Peptide Position
a Sequence MW Length
b Score rBA (%)
c
60029 275–283 SMYLPGAEV 965.5 9 26 97.2
60030 131–139 LLAPGGNSM 858.4 9 25 80.0
60031 118–127 TLMKKDKYTL 1239.7 10 24 43.3
MW¼molecular weight; rBA¼relative binding affinity.
aThe given numbers indicate the position of the peptide in the amino-acid sequence of SOX2.
bNumber of amino acids.
cThe relative binding affinities were determined by comparing the inhibition of the reporter peptide binding by the analysed peptides in relation to the inhibition obtained with a
positive control peptide, which was set as 100%. The positive control peptide was YLLPAIVHI from RNA helicase p72 and the reporter peptide was ILK(FITC)EPVHGV from
HIV-1 reverse transcriptase. All peptides were used at a concentration of 10mM.
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